← Back to Search

Thiazolidinedione

Pioglitazone for Obesity

Phase < 1
Recruiting
Led By Michael D Jensen
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Non obese adults BMI between 18-25
Women will be premenopausal
Must not have
Initiation in patients with established New York Heart Associations (NYHA) class III or IV Heart failure.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4-9 months
Awards & highlights

Summary

This trial will help researchers understand how pioglitazone helps regulate insulin in obese patients, and what role abnormal proteins in fat cells play in that process.

Who is the study for?
This trial is for men and women aged 18-55, including premenopausal women. It's suitable for non-obese adults with a BMI of 18-25 and obese individuals with a BMI of 30-38. People allergic to pioglitazone or with severe heart failure (NYHA class III/IV) cannot participate.Check my eligibility
What is being tested?
The study investigates how the drug Pioglitazone affects fat cell metabolism in those with upper body obesity. It compares immediate weight loss strategies, deferred weight loss plans, and placebo effects on insulin's ability to control fat breakdown.See study design
What are the potential side effects?
Pioglitazone may cause side effects like fluid retention leading to swelling, potential weight gain, an increased risk of bone fractures especially in women, and could potentially worsen certain types of diabetic eye disease.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My BMI is between 18 and 25, so I am not obese.
Select...
I am a woman and have not gone through menopause.
Select...
I am between 18 and 55 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have severe heart failure (NYHA class III or IV).

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4-9 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4-9 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adipocytes
Adipocyte response to insulin - adipocyte G0S2 relative to ATGL.
Adipocyte response to insulin - perilipin 1 and FSP27 relative to HSL and ATGL
+1 more

Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: Immediate weight loss - placeboActive Control2 Interventions
Upper body obese participants randomized to this group; all will begin their immediate participation in a comprehensive lifestyle obesity treatment program after completion of baseline studies. Half of the volunteers will be randomized to placebo during this period.
Group II: Deferred group - pioglitazoneActive Control2 Interventions
After baseline studies, UBO participants randomized to this group will wait without any intervention for 4 months, with continued monitoring to assure weight stability - this group will be the half of volunteers randomized to deferred weight loss intervention that are randomized to pioglitazone. They will be monitored to prevent the usual but modest weight gain associated with pioglitazone. They will be on pioglitazone during the 'wait' period. At the end of this 'wait' period they will be enrolled in the same comprehensive lifestyle obesity treatment program for 4 months, but without pioglitazone.
Group III: Immediate weight loss - pioglitazoneActive Control2 Interventions
Upper body obese participants randomized to this group; all will begin their immediate participation in a comprehensive lifestyle obesity treatment program after completion of baseline studies. Half of the volunteers will be randomized to pioglitazone during this period.
Group IV: Deferred control group - placeboPlacebo Group2 Interventions
After baseline studies, UBO participants randomized to this group will wait without any intervention for 4 months, with continued monitoring to assure weight stability - this group will be the half of volunteers randomized to deferred weight loss intervention that are also randomized to placebo. At the end of this 'wait' period they will be enrolled in the same comprehensive lifestyle obesity treatment program for 4 months, but without placebo.

Find a Location

Who is running the clinical trial?

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,381 Previous Clinical Trials
4,315,038 Total Patients Enrolled
453 Trials studying Obesity
588,901 Patients Enrolled for Obesity
Mayo ClinicLead Sponsor
3,255 Previous Clinical Trials
3,835,342 Total Patients Enrolled
86 Trials studying Obesity
14,715 Patients Enrolled for Obesity
Michael D JensenPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
20 Total Patients Enrolled
1 Trials studying Obesity
20 Patients Enrolled for Obesity

Media Library

Obesity Research Study Groups: Deferred control group - placebo, Immediate weight loss - placebo, Deferred group - pioglitazone, Immediate weight loss - pioglitazone
~4 spots leftby Dec 2024